Koa Wealth Management LLC cut its holdings in Danaher Co. (NYSE:DHR – Free Report) by 0.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 16,529 shares of the conglomerate’s stock after selling 136 shares during the quarter. Danaher makes up about 3.5% of Koa Wealth Management LLC’s holdings, making the stock its 7th largest holding. Koa Wealth Management LLC’s holdings in Danaher were worth $4,595,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of DHR. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Danaher in the second quarter valued at about $51,000. Financial Connections Group Inc. purchased a new position in shares of Danaher in the second quarter worth about $51,000. Finally, Western Pacific Wealth Management LP acquired a new stake in shares of Danaher during the first quarter worth about $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Price Performance
Shares of NYSE DHR opened at $230.51 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a market cap of $166.49 billion, a PE ratio of 43.99, a PEG ratio of 4.44 and a beta of 0.85. Danaher Co. has a one year low of $206.30 and a one year high of $281.70. The firm has a fifty day moving average of $262.20 and a 200 day moving average of $260.38.
Danaher Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is presently 20.61%.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on DHR shares. Evercore ISI raised their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. UBS Group reduced their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. The Goldman Sachs Group upped their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Leerink Partners lifted their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Robert W. Baird lowered their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $287.16.
View Our Latest Report on Danaher
Insider Buying and Selling
In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 18.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by company insiders.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- The 3 Best Blue-Chip Stocks to Buy Now
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Insider Trades May Not Tell You What You Think
- Time to Load Up on Home Builders?
- When to Sell a Stock for Profit or Loss
- Flutter Entertainment Can Be a Blue-Chip Sports Betting Stock
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.